{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:04:55Z","timestamp":1732035895167,"version":"3.28.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Jiangsu Nhwa pharmaceutical Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The purpose of this work was to develop ziprasidone\u2013phospholipid complex (ZIP-PLC) in sustained-release pellets to enhance the oral bioavailability and overcome the food effect of ziprasidone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ziprasidone\u2013phospholipid complex was formulated by solvent-evaporation method. The complexes were characterized by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and solubility testing. The optimized ZIP-PLC was used to prepare ZIP-PLC sustained-release pellets via extrusion\u2013spheronization method. The pellets were characterized by in vitro drug-release studies and administered to fasted and fed beagle dogs, and their pharmacokinetics were compared with commercial formulation Zeldox capsule as a control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The results of FTIR, SEM, DSC and PXRD studies confirmed the formation of phospholipid complex. Solubility studies showed there was a higher solubility in water for ZIP-PLC than monohydrate ziprasidoe. The in vitro release rate of ziprasidone from the ZIP-PLC sustained-release pellet exhibited controlled-release characteristics with over 95% total release in 12 h. Pharmacokinetic studies in beagle dogs showed ziprasidone with prolong actions, and no food effect was achieved simultaneously in ZIP-PLC sustained-release pellet compared with Zeldox capsule.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results indicated a sustained release with prolonged actions of schizophrenia and bipolar disorder treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12510","type":"journal-article","created":{"date-parts":[[2016,1,10]],"date-time":"2016-01-10T11:33:16Z","timestamp":1452425596000},"page":"185-194","source":"Crossref","is-referenced-by-count":6,"title":["Preparation and evaluation of ziprasidone\u2013phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect"],"prefix":"10.1093","volume":"68","author":[{"given":"Yanfei","family":"Miao","sequence":"first","affiliation":[{"name":"School of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University , Nanjing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoguang","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nanjing Tech University , Nanjing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nanjing Tech University , Nanjing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingkai","family":"Ouyang","sequence":"additional","affiliation":[{"name":"School of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University , Nanjing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2024103012563556400_jphp12510-cit-0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14656566.6.2.337","article-title":"Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness","volume":"6","author":"Harvey","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2024103012563556400_jphp12510-cit-0002","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/03639040802020536","article-title":"CNS disorders-current treatment options and the prospects for advanced therapies","volume":"34","author":"DiNunzio","year":"2008","journal-title":"Drug Dev Ind Pharm"},{"key":"2024103012563556400_jphp12510-cit-0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the Clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"},{"key":"2024103012563556400_jphp12510-cit-0004","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/14737175.6.8.1129","article-title":"Ziprasidone: efficacy and safety in patients with bipolar disorder","volume":"6","author":"Patel","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"2024103012563556400_jphp12510-cit-0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12325-009-0055-0","article-title":"Using oral ziprasidone effectively: the food effect and dose-response","volume":"26","author":"Citrome","year":"2009","journal-title":"J Adv Ther"},{"key":"2024103012563556400_jphp12510-cit-0006","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single-and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012563556400_jphp12510-cit-0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.pra.0000369971.64908.dc","article-title":"How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone","volume":"16","author":"Lincoln","year":"2010","journal-title":"J Psychiatr Pract"},{"key":"2024103012563556400_jphp12510-cit-0008","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1517\/14656566.2010.507630","article-title":"Strategies for successful clinical management of schizophrenia with ziprasidone","volume":"11","author":"Fagiolini","year":"2010","journal-title":"Expert Opin Pharmacother"},{"volume-title":"US Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection, LAB-0272-3.0 [package insert]","author":"Pfizer, Inc.","key":"2024103012563556400_jphp12510-cit-0009"},{"key":"2024103012563556400_jphp12510-cit-0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins Diana","year":"2002","journal-title":"J Clin Psychiatr"},{"key":"2024103012563556400_jphp12510-cit-0011","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/00003088-200544110-00002","article-title":"Pharmacokinetics and therapeutics of acute intramuscular ziprasidone","volume":"44","author":"Preskom","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024103012563556400_jphp12510-cit-0012","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/js980109t","article-title":"Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether","volume":"87","author":"Kim","year":"1998","journal-title":"J Pharm Sci"},{"key":"2024103012563556400_jphp12510-cit-0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2012.02.004","article-title":"In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations","volume":"428","author":"Avinash","year":"2012","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0014","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s11095-011-0505-7","article-title":"Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect","volume":"28","author":"Avinash","year":"2011","journal-title":"Pharm Res"},{"key":"2024103012563556400_jphp12510-cit-0015","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1021\/mp3003607","article-title":"Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state","volume":"9","author":"Avinash","year":"2012","journal-title":"Mol Pharm"},{"key":"2024103012563556400_jphp12510-cit-0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2013.10.043","article-title":"Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation","volume":"460","author":"Singh","year":"2014","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0017","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/jps.22393","article-title":"Bioavailability enhancement of curcumin by complexation with phosphatidylcholine","volume":"100","author":"Gupta","year":"2011","journal-title":"J Pharm Sci"},{"key":"2024103012563556400_jphp12510-cit-0018","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/aps.2010.55","article-title":"Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate\/phospholipid-mixed micelles","volume":"31","author":"Yu","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"2024103012563556400_jphp12510-cit-0019","first-page":"54","article-title":"Improving permeability and oral absorption of mangiferin by phospholipid complexation","volume":"93 C","author":"Hequn","year":"2014","journal-title":"Fitoterapia"},{"key":"2024103012563556400_jphp12510-cit-0020","first-page":"79","article-title":"Coating of multiparticulates using polymeric dispersions","volume-title":"Multiparticulate Oral Drug Delivery","author":"Fukumori","year":"1997"},{"key":"2024103012563556400_jphp12510-cit-0021","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejpb.2010.07.011","article-title":"Development and evaluation of selfmicroemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats","volume":"76","author":"Setthacheewakul","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012563556400_jphp12510-cit-0022","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2006.07.011","article-title":"Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system","volume":"65","author":"Serratoni","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012563556400_jphp12510-cit-0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2009.12.008","article-title":"Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex","volume":"387","author":"Yue","year":"2010","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.08.014","article-title":"Solid self-microemulsifying nitrendipine pellets: preparation and in vitro\/in vivo evaluation","volume":"383","author":"Wang","year":"2010","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0025","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1208\/s12249-010-9501-1","article-title":"Development of sustained release capsules containing coated matrix granules of metoprolol tartrate","volume":"11","author":"Siddique","year":"2010","journal-title":"AAPS Pharm Sci Technol"},{"key":"2024103012563556400_jphp12510-cit-0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2014.08.006","article-title":"Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods","volume":"474","author":"Guo","year":"2014","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.06.056","article-title":"Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability","volume":"473","author":"Jena","year":"2014","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpharm.2005.10.001","article-title":"The preparation of silybin phospholipid complex and the study on its pharmacokinetics in rats","volume":"307","author":"Yanyu","year":"2006","journal-title":"Int J Pharm"},{"key":"2024103012563556400_jphp12510-cit-0029","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2478\/v10007-009-0023-x","article-title":"Development and physicochemical evaluation of pharmacosomes of diclofenac","volume":"59","author":"Semalty","year":"2009","journal-title":"Acta Pharm"},{"key":"2024103012563556400_jphp12510-cit-0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/IJN.S39526","article-title":"A novel drug-phospholipid complex enriched with micelles: pre-paration and evaluation in vitro and in vivo","volume":"8","author":"Xia","year":"2013","journal-title":"Int J Nanomedicine"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/2\/185\/60231246\/jphp12510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/2\/185\/60231246\/jphp12510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:27:15Z","timestamp":1730312835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/68\/2\/185\/6128965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12510","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2016,2,1]]}}}